Press Releases
PDF VersionCollaboration will combine KYAN’s Optim.AI™ platform with Nouveau’s nanomedicine discovery capabilities to identify and develop novel, synthetically lethal drug combinations for cancer [NEW YORK, September 29, 2026] — Nouveau Biosciences, a biotechnology company developing precision-targeted nanomedicines for cancer, today announced that it has entered into an agreement with KYAN Technologies, a functional precision medicine company […]
Renowned oncologist, healthcare innovator and biotechnology entrepreneur brings decades of experience in cancer research, cellular medicine and precision oncology to Nouveau [NEW YORK, September 22, 2026] — Nouveau Biosciences, a biotechnology company developing precision-targeted nanomedicines for cancer, today announced the appointment of Andrew L. Pecora, M.D., FACP, CPE, as Chairman of its Scientific Advisory Board. […]
Collaboration will combine DarwinHealth’s systems-biology, AI, and computational oncology platform with Nouveau Biosciences’ precision nanotherapeutic technology to develop therapies tailored to cancer biology [NEW YORK, September 15, 2025] — Nouveau Biosciences, a biotechnology company developing precision nanomedicines for cancer, today announced that it has entered into a collaboration with DarwinHealth™ to identify and develop novel therapeutic […]
World-renowned MIT scientist and pioneering biomedical engineer brings decades of leadership in drug delivery, biomaterials and biotechnology to Nouveau’s precision oncology platform [NEW YORK, September 8, 2026] — Nouveau Biosciences, a biotechnology company developing precision-targeted nanomedicines for cancer, today announced the appointment of Robert Langer, Sc.D., David H. Koch (1962) Institute Professor at the Massachusetts […]
[New York, NY – June 5, 2026] – Nouveau Biosciences is proud to announce the recruitment of Deepthi Damera, Ph.D. to lead its nanochemistry programs at Nouveau Research Technologies, the company laboratory. Dr. Damera is a highly accomplished biophysicist who has spent the past decade intimately involved in all aspects of nanotechnology, from fabrication to biophysical characterization. […]
[New York, NY – February, 10, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a second Licensing Agreement with the University of Virginia (UVA) to expand the company’s pipeline. The Licensing Agreement ratifies Nouveau’s rights to six additional novel nanomedicine […]
New York, NY and Tampa, FL – January 5, 2026 – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, and CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships, today announced that the two organizations have entered into […]
Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies [New York, NY – January 5, 2026] Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture […]
[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering nanomedicine and targeted oncology therapeutics, today announced the appointment of Joseph Turgeon as Chief Operating Officer. Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, […]
[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering next-generation nanomedicine and targeted oncology therapeutics, today announced the appointment of Keith M. McGahan as Chief Legal Officer. Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track […]